Pfizer's HYMPAVZI Shows Significant Bleeding Outcome Improvements in Hemophilia A/B Patients
Written by Emily J. Thompson, Senior Investment Analyst
Source: Businesswire
Updated: 55 minutes ago0mins
- Clinical Trial Results: Pfizer presented at the 67th American Society of Hematology Annual Meeting that HYMPAVZI demonstrated superiority in reducing bleeding events in hemophilia A/B patients compared to traditional treatments, indicating its potential to improve patients' quality of life significantly.
- Administration Convenience: HYMPAVZI is administered via a straightforward once-weekly subcutaneous injection, which simplifies the treatment process and reduces the need for laboratory monitoring, thereby enhancing patient adherence and treatment experience.
- Safety Assessment: Among 51 participants, HYMPAVZI was well tolerated with no deaths or thromboembolic events reported, and 38 patients experienced adverse events, primarily mild to moderate, demonstrating the drug's good tolerability.
- Market Outlook: Pfizer has submitted approval applications for HYMPAVZI to the FDA and EMA, and if approved, it will provide a new treatment option for over 800,000 hemophilia patients globally, further solidifying Pfizer's leadership in the hemophilia treatment market.
PFE.N
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 29.08 USD with a low forecast of 24.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
4 Buy
10 Hold
1 Sell
Hold
Current: 25.700
Low
24.00
Averages
29.08
High
34.00
Current: 25.700
Low
24.00
Averages
29.08
High
34.00
Guggenheim
Buy
maintain
$33 -> $35
2025-11-24
Reason
Guggenheim
Price Target
$33 -> $35
2025-11-24
maintain
Buy
Reason
Guggenheim raised the firm's price target on Pfizer to $35 from $33 and keeps a Buy rating on the shares. Pfizer's acquisition of Metsera is "a wise strategic move" to gain traction in the rapidly growing obesity market following recent setbacks with the company's internal oral GLP-1 programs, the analyst tells investors.
Scotiabank
Outperform
initiated
$30
2025-11-12
Reason
Scotiabank
Price Target
$30
2025-11-12
initiated
Outperform
Reason
Scotiabank initiated coverage of Pfizer with an Outperform rating and $30 price target.
BofA
Tim Anderson
Neutral
maintain
$28
2025-10-01
Reason
BofA
Tim Anderson
Price Target
$28
2025-10-01
maintain
Neutral
Reason
The timing of the "deal" announced between the U.S. and Pfizer on drug pricing "may have come as a surprise," but the substance of it didn't, in the opinion of BofA analyst Tim Anderson, whose view over the last weeks-to-months has been that the drug industry might well escape any real pain when negotiating on issues like "most favored nation" drug pricing. Press releases from the White House and from Pfizer "largely lack specifics, but both read as benign," adds the analyst, who calls the agreement "a loose collection of measures that likely doesn't cost Pfizer much, yet still provides the Administration with a political win." The firm keeps a Neutral rating and $28 price target on Pfizer shares.
Wells Fargo
Cerena Chen
Overweight -> Equal Weight
downgrade
$65 -> $54
2025-09-29
Reason
Wells Fargo
Cerena Chen
Price Target
$65 -> $54
2025-09-29
downgrade
Overweight -> Equal Weight
Reason
Wells Fargo analyst Cerena Chen downgraded Metsera (MTSR) to Equal Weight from Overweight with a price target of $54, down from $65, after Pfizer (PFE) announced an agreement to acquire Metsera for $4.9B upfront and total potential deal value of about $7.3B contingent on hitting various pipeline-related targets. The firm adds that here's little likelihood of other bidders coming in at this time as other players have likely already looked at the company.
See All Ratings
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What factors contributed to Valneva's stock increase after the vaccine trial results?
Why is the FDA implementing stricter approval standards for vaccines?
How might Pfizer's collaboration with Valneva impact its 2026 financial outlook?
What are the potential market implications of the UK-US drug pricing agreement?